ExchangeDEX+
Buy CryptoMarketsSpotFuturesGOLDEarnEvent Center
More
Commodity Zero-Fee Gala
NIJMEGEN, The Netherlands, Jan. 26, 2026 /PRNewswire/ — Mair Therapeutics, a Dutch biotechnology company pioneering lysosomal-targeted therapies for neurodegenerativeNIJMEGEN, The Netherlands, Jan. 26, 2026 /PRNewswire/ — Mair Therapeutics, a Dutch biotechnology company pioneering lysosomal-targeted therapies for neurodegenerative

Mair Therapeutics Announces Scientific Collaboration with Radboud University to Advance TMEM175 Agonists for Parkinson’s Disease

Author: AI JournalSource: AI Journal
2026/01/26 20:32
3 min read

NIJMEGEN, The Netherlands, Jan. 26, 2026 /PRNewswire/ — Mair Therapeutics, a Dutch biotechnology company pioneering lysosomal-targeted therapies for neurodegenerative diseases, today announced a scientific collaboration with Radboud University to accelerate the discovery of small-molecule agonists of TMEM175, a lysosomal ion channel genetically linked to Parkinson’s disease.

Mair Therapeutics Announces Scientific Collaboration with Radboud University to Advance Program for Parkinson’s Disease

TMEM175 plays a key role in maintaining lysosomal homeostasis, which is essential for the clearance of misfolded proteins such as alpha-synuclein. Genetic studies have linked TMEM175 dysfunction to increased risk of Parkinson’s disease, while protective variants have been shown to reduce disease susceptibility. Mair’s drug discovery platform is focused on identifying small molecules that enhance TMEM175 activity and restore lysosomal function.

Under this collaboration, Dr. Marijn Kuijpers’ laboratory at the Donders Centre for Neuroscience, Faculty of Science, Radboud University, will assess a portfolio of TMEM175-targeting compounds developed by Mair Therapeutics. The compounds will be evaluated in human neuron models derived from Parkinson’s disease and healthy donor cells, using assays focused on lysosomal pH regulation and degradation capacity—two critical functions impaired in Parkinson’s disease.

“Parkinson’s disease remains one of the most pressing medical challenges of our time, and targeting lysosomal dysfunction offers a promising path forward,” said Dr. Vasily Kazey, CEO of Mair Therapeutics. “We are excited to collaborate with Radboud University, whose deep expertise in neuronal biology and Parkinson’s research will be instrumental in validating our therapeutic approach.”

The collaboration underscores Mair’s commitment to building partnerships within the East Netherlands’ neuroscience and innovation ecosystem. The company, which recently launched with backing from Torrey Pines Investment and Oost NL, is headquartered in Nijmegen, a leading hub for Parkinson’s research and home to the Parkinson expertise center led by Prof. Dr. Bas Bloem at Radboudumc.

About Mair Therapeutics
Mair Therapeutics is a biotechnology company dedicated to developing first-in-class small-molecule therapeutics that target lysosomal ion channels in neurodegenerative diseases. Its lead program focuses on TMEM175 agonists for Parkinson’s disease. Headquartered in Nijmegen, Mair is supported by Torrey Pines Investment, Oost NL, and Expert Systems. For more information, visit www.mairtx.com.

About Radboud University
Radboud University is one of the leading academic institutions in the Netherlands, internationally recognized for excellence in life sciences and neuroscience. The Kuijpers Lab at the Donders Institute focuses on understanding organelle dynamics and intracellular trafficking in neurons, with an emphasis on lysosomal biology and neurodegenerative disease models. Learn more at www.kuijperslab.com.

Media Contact
info@mairtx.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/mair-therapeutics-announces-scientific-collaboration-with-radboud-university-to-advance-tmem175-agonists-for-parkinsons-disease-302669941.html

SOURCE Mair Therapeutics

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:
#RWA

You May Also Like

Wormhole launches reserve tying protocol revenue to token

Wormhole launches reserve tying protocol revenue to token

The post Wormhole launches reserve tying protocol revenue to token appeared on BitcoinEthereumNews.com. Wormhole is changing how its W token works by creating a new reserve designed to hold value for the long term. Announced on Wednesday, the Wormhole Reserve will collect onchain and offchain revenues and other value generated across the protocol and its applications (including Portal) and accumulate them into W, locking the tokens within the reserve. The reserve is part of a broader update called W 2.0. Other changes include a 4% targeted base yield for tokenholders who stake and take part in governance. While staking rewards will vary, Wormhole said active users of ecosystem apps can earn boosted yields through features like Portal Earn. The team stressed that no new tokens are being minted; rewards come from existing supply and protocol revenues, keeping the cap fixed at 10 billion. Wormhole is also overhauling its token release schedule. Instead of releasing large amounts of W at once under the old “cliff” model, the network will shift to steady, bi-weekly unlocks starting October 3, 2025. The aim is to avoid sharp periods of selling pressure and create a more predictable environment for investors. Lockups for some groups, including validators and investors, will extend an additional six months, until October 2028. Core contributor tokens remain under longer contractual time locks. Wormhole launched in 2020 as a cross-chain bridge and now connects more than 40 blockchains. The W token powers governance and staking, with a capped supply of 10 billion. By redirecting fees and revenues into the new reserve, Wormhole is betting that its token can maintain value as demand for moving assets and data between chains grows. This is a developing story. This article was generated with the assistance of AI and reviewed by editor Jeffrey Albus before publication. Get the news in your inbox. Explore Blockworks newsletters: Source: https://blockworks.co/news/wormhole-launches-reserve
Share
BitcoinEthereumNews2025/09/18 01:55
Kalshi debuts ecosystem hub with Solana and Base

Kalshi debuts ecosystem hub with Solana and Base

The post Kalshi debuts ecosystem hub with Solana and Base appeared on BitcoinEthereumNews.com. Kalshi, the US-regulated prediction market exchange, rolled out a new program on Wednesday called KalshiEco Hub. The initiative, developed in partnership with Solana and Coinbase-backed Base, is designed to attract builders, traders, and content creators to a growing ecosystem around prediction markets. By combining its regulatory footing with crypto-native infrastructure, Kalshi said it is aiming to become a bridge between traditional finance and onchain innovation. The hub offers grants, technical assistance, and marketing support to selected projects. Kalshi also announced that it will support native deposits of Solana’s SOL token and USDC stablecoin, making it easier for users already active in crypto to participate directly. Early collaborators include Kalshinomics, a dashboard for market analytics, and Verso, which is building professional-grade tools for market discovery and execution. Other partners, such as Caddy, are exploring ways to expand retail-facing trading experiences. Kalshi’s move to embrace blockchain partnerships comes at a time when prediction markets are drawing fresh attention for their ability to capture sentiment around elections, economic policy, and cultural events. Competitor Polymarket recently acquired QCEX — a derivatives exchange with a CFTC license — to pave its way back into US operations under regulatory compliance. At the same time, platforms like PredictIt continue to push for a clearer regulatory footing. The legal terrain remains complex, with some states issuing cease-and-desist orders over whether these event contracts count as gambling, not finance. This is a developing story. This article was generated with the assistance of AI and reviewed by editor Jeffrey Albus before publication. Get the news in your inbox. Explore Blockworks newsletters: Source: https://blockworks.co/news/kalshi-ecosystem-hub-solana-base
Share
BitcoinEthereumNews2025/09/18 04:40
Optimizely Named a Leader in the 2026 Gartner® Magic Quadrant™ for Personalization Engines

Optimizely Named a Leader in the 2026 Gartner® Magic Quadrant™ for Personalization Engines

Company recognized as a Leader for the second consecutive year NEW YORK, Feb. 5, 2026 /PRNewswire/ — Optimizely, the leading digital experience platform (DXP) provider
Share
AI Journal2026/02/06 00:47